(Q36677383)

15 August 2017

1 reference

title

Novel inhibitors of the early steps of the HIV-1 life cycle (English)

1 reference

15 August 2017

Paola Citterio

1

1 reference

15 August 2017

Stefano Rusconi

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

16

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

11-23

1 reference

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Signals and receptors involved in recruitment of inflammatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Identification of a major co-receptor for primary isolates of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Blocking the docking of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

HIV infection is blocked in vitro by recombinant soluble CD4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

New advances in HIV entry inhibitors development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

HIV entry and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Protein design of an HIV-1 entry inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

CCR5 antagonists as anti-HIV-1 agents. 1. Synthesis and biological evaluation of 5-oxopyrrolidine-3-carboxamide derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.1.11

21 January 2018

Identifiers

DOI

10.1517/13543784.16.1.11

1 reference

15 August 2017

1 reference